E M Horwitz

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi request reprint Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    J Urol 173:797-802. 2005
  2. ncbi request reprint Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 107:1496-502. 2006
  3. doi request reprint Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
    Eric M Horwitz
    Fox Chase Cancer Center, Department of Radiation Oncology, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    J Clin Oncol 26:2497-504. 2008
  4. ncbi request reprint The treatment of non-metastatic prostate cancer with external beam radiation therapy
    E M Horwitz
    Departments of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Minerva Urol Nefrol 56:173-88. 2004
  5. ncbi request reprint Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 89:2018-24. 2000
  6. ncbi request reprint The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 100:538-43. 2004
  7. ncbi request reprint Is there a role for short-term hormone use in the treatment of nonmetastatic prostate cancer?
    E M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Radiat Oncol Investig 7:249-59. 1999
  8. ncbi request reprint Dose selection for prostate cancer patients based on dose comparison and dose response studies
    G E Hanks
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 46:823-32. 2000
  9. ncbi request reprint Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer
    W H Pinover
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 47:649-54. 2000
  10. ncbi request reprint Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 57:915-28. 2003

Detail Information

Publications81

  1. ncbi request reprint Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    J Urol 173:797-802. 2005
    ..In this report we determined the sensitivity and specificity of several BF definitions using distant failure (DF) alone or clinical failure (CF), defined as local failure (LF) and/or DF...
  2. ncbi request reprint Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 107:1496-502. 2006
    ....
  3. doi request reprint Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
    Eric M Horwitz
    Fox Chase Cancer Center, Department of Radiation Oncology, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    J Clin Oncol 26:2497-504. 2008
    ..To determine whether adding 2 years of androgen-deprivation therapy (ADT) improved outcome for patients electively treated with ADT before and during radiation therapy (RT)...
  4. ncbi request reprint The treatment of non-metastatic prostate cancer with external beam radiation therapy
    E M Horwitz
    Departments of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Minerva Urol Nefrol 56:173-88. 2004
    ..The appropriate use of adjuvant hormones as well as the complications of these treatments will also be discussed...
  5. ncbi request reprint Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 89:2018-24. 2000
    ..The purpose of this study was to analyze the extent of hypoxia in prostate carcinoma tumors using the Eppendorf pO(2) microelectrode and correlate this with pretreatment characteristics and prognostic factors...
  6. ncbi request reprint The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 100:538-43. 2004
    ..However, there is little direct evidence that dose escalation has an impact on distant metastasis (DM) or overall mortality (OM). These associations were examined in the current study...
  7. ncbi request reprint Is there a role for short-term hormone use in the treatment of nonmetastatic prostate cancer?
    E M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Radiat Oncol Investig 7:249-59. 1999
    ..Long-term observation will be necessary to see if improvements in bNED control will translate into improvements in overall survival...
  8. ncbi request reprint Dose selection for prostate cancer patients based on dose comparison and dose response studies
    G E Hanks
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 46:823-32. 2000
    ..To better define the appropriate dose for individual prostate cancer patients treated with three-dimensional conformal radiation therapy (3D CRT)...
  9. ncbi request reprint Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer
    W H Pinover
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 47:649-54. 2000
    ....
  10. ncbi request reprint Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 57:915-28. 2003
    ..To report the long-term outcome for patients with Stage T1-T2 adenocarcinoma of the prostate definitively irradiated in the prostate-specific antigen (PSA) era...
  11. ncbi request reprint Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques
    E M Horwitz
    Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, Pennsylvania 19111, USA
    Cancer 92:1281-7. 2001
    ....
  12. ncbi request reprint Patterns and fate of PSA bouncing following 3D-CRT
    A L Hanlon
    Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 50:845-9. 2001
    ....
  13. ncbi request reprint Dose response in prostate cancer with 8-12 years' follow-up
    Gerald E Hanks
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 54:427-35. 2002
    ....
  14. ncbi request reprint The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 59:1383-91. 2004
    ....
  15. ncbi request reprint The cost effectiveness of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer
    E M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 45:1219-25. 1999
    ..However, in this era of cost consciousness and limited resources, the cost effectiveness of 3DCRT compared with conventional external beam irradiation (CRT) remains unexamined...
  16. ncbi request reprint PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis
    Michael E Ray
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 64:1140-50. 2006
    ....
  17. ncbi request reprint Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
    Stephen F Andrews
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 104:299-304. 2005
    ..There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes...
  18. ncbi request reprint Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?
    Khanh H Nguyen
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:377-83. 2003
    ....
  19. ncbi request reprint Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 60:634-9. 2002
    ..To investigate whether low partial pressure of oxygen (PO2) in prostate cancer (CaP) predicts for biochemical outcome after radiotherapy. We previously reported that hypoxic regions exist in human CaP...
  20. ncbi request reprint Evidence for cure of 'young' men with prostate cancer
    G E Hanks
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 15:563-7; discussion 571-4. 2001
    ..Few failures occur after 5 years' follow-up and the percentage cured is similar to that with prostatectomy, with much less morbidity. Appropriate dose is necessary to optimize outcome...
  21. ncbi request reprint The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 67:1082-7. 2007
    ..To investigate the prognostic utility of the proportion of prostate biopsy tissue containing Gleason pattern 4 or 5 (GP4/5) after definitive radiotherapy (RT) for prostate cancer...
  22. ncbi request reprint Brachytherapy for prostate cancer: follow-up and management of treatment failures
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Urol Clin North Am 30:737-50, viii-ix. 2003
    ..Finally, a comprehensive review of the management of local recurrence following brachytherapy is offered...
  23. pmc Radiation dose and late failures in prostate cancer
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 67:1074-81. 2007
    ..To quantify the impact of radiation dose escalation on the timing of biochemical failure (BF) and distant metastasis (DM) for prostate cancer treated with radiotherapy (RT) alone...
  24. ncbi request reprint Matched-cohort analysis of patients with prostate cancer followed with observation or treated with three-dimensional conformal radiation therapy
    Noel M Kramer
    Departments of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    BJU Int 94:59-62. 2004
    ..To compare the outcome of similar patients with prostate cancer treated by either observation or three-dimensional conformal radiation therapy (3-DCRT)...
  25. ncbi request reprint Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure
    Michael E Ray
    Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0010, USA
    Urology 68:1257-62. 2006
    ..To determine whether nadir prostate-specific antigen (PSA) levels within 12 months (nadir PSA12) after completion of radiotherapy (RT) can be used as an early marker of recurrence risk...
  26. ncbi request reprint Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 61:695-701. 2005
    ..To determine whether the radiation dose is a determinant of clinical outcome in patients with a lymph node risk of >15% treated using whole pelvic (WP), partial pelvic (PP), or prostate only (PO) fields...
  27. ncbi request reprint A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy
    Derek B Chism
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 59:380-5. 2004
    ..Two models for stratification of prostate cancer aggressiveness predominate for the purposes of daily treatment decision making. This study investigates the relationships between these two clinically popular models...
  28. ncbi request reprint Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 61:1291-8. 2005
    ..The temporal kinetics of posttreatment PSA levels was examined to define the error in the classification of BF...
  29. pmc What dose of external-beam radiation is high enough for prostate cancer?
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:682-9. 2007
    ..To quantify the radiotherapy dose-response of prostate cancer, adjusted for prognostic factors in a mature cohort of men treated relatively uniformly at a single institution...
  30. pmc How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 70:1487-91. 2008
    ..This study sought to determine whether the initial PSA increase from undetectable after completion of all treatment predicts for eventual biochemical failure (BF)...
  31. pmc Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 110:68-80. 2007
    ..The authors hypothesized that early failures due to subclinical micrometastasis at presentation could be differentiated from late failures due to local persistence...
  32. ncbi request reprint Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies
    Noel M Kramer
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111 2497, USA
    Head Neck 27:406-14. 2005
    ..The purpose of this study is to report the initial clinical results of the Fox Chase phase I and II prospective reirradiation and chemotherapy studies...
  33. ncbi request reprint Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy
    Wayne H Pinover
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 97:1127-33. 2003
    ....
  34. pmc A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 71:338-45. 2008
    ..To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and (125)I transperineal permanent prostate seed implant ((125)I) for patients with low-risk prostate cancer...
  35. ncbi request reprint Update on the treatment of prostate cancer with external beam irradiation
    E M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Prostate 37:195-206. 1998
    ....
  36. ncbi request reprint Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy
    E M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 49:947-56. 2001
    ..This analysis excludes those patients with positive lymph nodes or postprostatectomy to determine the benefit of adjuvant hormones in men with locally advanced nonmetastatic prostate cancer receiving definitive RT...
  37. ncbi request reprint Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 67:327-33. 2007
    ..To assess long-term prostate-specific antigen (PSA) outcome after permanent prostate brachytherapy (BT) and identify predictors of improved disease-free survival...
  38. ncbi request reprint Comparison of biochemical failure definitions for permanent prostate brachytherapy
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 65:1487-93. 2006
    ..To assess prostate-specific antigen (PSA) failure definitions for patients with Stage T1-T2 prostate cancer treated by permanent prostate brachytherapy...
  39. ncbi request reprint Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Urol 169:2153-7; discussion 2157-9. 2003
    ..We evaluated the impact of backdating on no biochemical evidence of disease (bNED) control and suggest changes in the definition...
  40. ncbi request reprint Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control
    Joseph M Kaminski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 52:888-92. 2002
    ..Two subgroups were studied: favorable (PSA <10 ng/mL, Gleason score 2-6, and T1-T2A) and unfavorable (one or more: PSA >/=10 ng/mL, Gleason score 7-10, T2B-T3)...
  41. ncbi request reprint Hypoxia in human prostate carcinoma: an Eppendorf PO2 study
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Am J Clin Oncol 24:458-61. 2001
    ..More patients will be accrued to this study to ultimately correlate the oxygenation status in prostate carcinoma tumors with treatment outcome...
  42. ncbi request reprint Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer
    Andre Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 66:408-15. 2006
    ....
  43. ncbi request reprint Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy
    Corey J Langer
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Invest 24:164-73. 2006
    ....
  44. ncbi request reprint Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Nat Clin Pract Oncol 2:12-3. 2005
  45. ncbi request reprint A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 29:458-62. 2006
    ..The purpose of this report is to determine whether any specific magnitude in the prostate specific antigen (PSA) bounce predicted for a clinically poorer outcome...
  46. doi request reprint Rectal dose variation during the course of image-guided radiation therapy of prostate cancer
    Lili Chen
    Radiation Oncology Department, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Radiother Oncol 95:198-202. 2010
    ..To investigate the change in rectal dose during the treatment course for intensity-modulated radiotherapy (IMRT) of prostate cancer with image-guidance...
  47. doi request reprint Gains from real-time tracking of prostate motion during external beam radiation therapy
    Jin sheng Li
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Int J Radiat Oncol Biol Phys 75:1613-20. 2009
    ..To study the gains from real-time tracking of prostate motion and threshold-based intervention and the feasibility of margin reduction for external beam radiation therapy of prostate cancer...
  48. pmc Does treatment duration affect outcome after radiotherapy for prostate cancer?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 72:1402-7. 2008
    ..In prostate cancer, the overall treatment time can be considerable, as can the potential for treatment breaks. We evaluated the effect of elapsed treatment time on outcome after RT for prostate cancer...
  49. pmc Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death
    Pino Alcantara
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 109:41-7. 2007
    ..0001).CONCLUSIONS.nPSA12 is a strong independent predictor of outcome after RT alone for prostate cancer and should be useful in identifying patients at high risk for progression to metastasis and death...
  50. ncbi request reprint The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer
    Matthew C Abramowitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 112:55-60. 2008
    ..The objective of the current study was to compare ASTRO and Phoenix BF estimates as determinants of distant metastasis (DM), cause-specific mortality (CSM), and overall mortality (OM)...
  51. ncbi request reprint Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911
    Corey J Langer
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 25:4800-5. 2007
    ..Chemotherapy alone yields a median survival time (MST) of no more than 10 months and 1-year overall survival (OS) of 35% at best. Concurrent reirradiation and chemotherapy is an alternative strategy...
  52. ncbi request reprint Comparing computed tomography localization with daily ultrasound during image-guided radiation therapy for the treatment of prostate cancer: a prospective evaluation
    Steven J Feigenberg
    Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, Pennsylvania 19111, USA
    J Appl Clin Med Phys 8:2268. 2007
    ..The isocenter shifts generated by using a CT unit in the treatment room correlate highly with shifts produced by the BAT Ultrasound system...
  53. pmc Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 109:2011-5. 2007
    ..This case series of 6 patients is the first to report the outcome of ductal carcinoma treated with external beam radiotherapy...
  54. pmc Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 64:518-26. 2006
    ..The dosimetry and acute toxicity are described in the first 100 men enrolled in a randomized trial...
  55. ncbi request reprint Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 63:1455-62. 2005
    ..To compare several characteristics of alternative definitions of biochemical failure (BF) in men with extended follow-up after radiotherapy (RT) with or with androgen deprivation therapy (ADT) for prostate cancer...
  56. ncbi request reprint Radiation therapy dose escalation for prostate cancer: a rationale for IMRT
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    World J Urol 21:200-8. 2003
    ..The results of dose escalation, the ability of IMRT to reduce rectal and bladder exposure to high radiation doses and the use of new imaging methods to more accurately target the prostate are described...
  57. ncbi request reprint Advantages of using noncoplanar vs. axial beam arrangements when treating prostate cancer with intensity-modulated radiation therapy and the step-and-shoot delivery method
    Robert A Price
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 53:236-43. 2002
    ....
  58. ncbi request reprint Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:19-23. 2003
    ..However, little evidence is available to show that BF is associated with death for patents with prostate cancer treated with radiotherapy. We examined the relationship between BF and death from prostate cancer...
  59. ncbi request reprint Positive prostate biopsy laterality and implications for staging
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 62:298-303. 2003
    ..Prostate biopsy laterality status (unilateral versus bilateral positive) is part of clinical staging using American Joint Commission on Cancer criteria, but is rarely used...
  60. ncbi request reprint Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Urol Clin North Am 30:337-49, x. 2003
    ..In summary, advances in radiation oncology have led to significant gains in prostate cancer control. Clinical prognostic factor-based patient selection is central to the optimization of outcome...
  61. ncbi request reprint Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination
    Robert G Uzzo
    Department of Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 61:754-9. 2003
    ....
  62. ncbi request reprint Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement
    Derek B Chism
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 55:71-7. 2003
    ..To describe the frequency and magnitude of late GI and GU morbidity in prostate cancer patients treated to high dose levels with a simple three-dimensional conformal technique...
  63. ncbi request reprint Biochemical failure rates in prostate cancer patients predicted to have biologically insignificant tumors treated with three-dimensional conformal radiation therapy
    Noel M Kramer
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 53:277-81. 2002
    ....
  64. ncbi request reprint Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer
    Alexandra L Hanlon
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 58:43-52. 2004
    ....
  65. ncbi request reprint Prostate cancer radiotherapy dose response: an update of the fox chase experience
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    J Urol 171:1132-6. 2004
    ....
  66. ncbi request reprint Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 62:397-405. 2005
    ..To determine whether the use of androgen deprivation (AD) increases late morbidity when combined with high-dose three-dimensional conformal radiation therapy (3D-CRT)...
  67. ncbi request reprint What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 61:1003-10. 2005
    ..The purpose of this study was to determine what pretreatment (initial) PSA (iPSA) level, if any, warrants the addition of long-term androgen deprivation in the PSA era...
  68. ncbi request reprint Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 70:59-66. 2008
    ..The present study examined the clinical utility of the interval to biochemical failure (IBF) as a prognostic factor for distant metastasis (DM) and prostate cancer-specific mortality (PCSM) after radiotherapy...
  69. ncbi request reprint Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck
    A S Garden
    Department of Radiation Oncology, Unit 97, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 22:2856-64. 2004
    ..To define further the role of concurrent chemoradiotherapy for patients with advanced squamous carcinoma of the head and neck...
  70. ncbi request reprint Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio
    Alan E Nahum
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:391-401. 2003
    ....
  71. pmc Residual prostate cancer after radiotherapy: a study of radical cystoprostatectomy specimens
    David J Kaplan
    Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 72:654-8. 2008
    ..We investigated the relationship between prostate-specific antigen (PSA) and histologically residual CaP after definitive RT in patients undergoing radical cystoprostatectomy (RCP) for unrelated indications...
  72. doi request reprint Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 71:938-41. 2008
    ..The purpose of this study was to determine whether a history of TURP is associated with increased biochemical failure (BF) after definitive radiotherapy for prostate cancer...
  73. ncbi request reprint Treatment of prostate cancer with regional lymph node (N1) metastasis
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Radiat Oncol 13:121-9. 2003
    ..Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP...
  74. ncbi request reprint The Gleason score shift: score four and seven years ago
    Derek B Chism
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 56:1241-7. 2003
    ..There is some evidence that Gleason scores (GS) have shifted over time, although documentation of the extent to which this has occurred and its clinical significance is sparse...
  75. ncbi request reprint Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Radiother Oncol 66:173-9. 2003
    ....
  76. ncbi request reprint Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer
    R G Uzzo
    The Department of Urology, Fox Chase Cancer Centre, Temple University School of Medicine, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    BJU Int 93:955-60. 2004
    ....
  77. ncbi request reprint Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups
    Howard D Thames
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, and Department of Radiation Oncology, William Beaumont Hospital, Deroit, MI, USA
    Int J Radiat Oncol Biol Phys 65:975-81. 2006
    ....
  78. ncbi request reprint Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995
    Howard Thames
    Department of Biomathematics, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 57:929-43. 2003
    ....
  79. ncbi request reprint Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02
    Gerald E Hanks
    Fox Chase Cancer Center and Radiation Therapy Oncology Group, Phialdelphia, PA 19107, USA
    J Clin Oncol 21:3972-8. 2003
    ....
  80. ncbi request reprint In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046
    Mark K Buyyounouski
    Int J Radiat Oncol Biol Phys 60:1664-5; author reply 1666. 2004
  81. ncbi request reprint Androgen suppression plus radiation therapy for prostate cancer
    Eric M Horwitz
    JAMA 292:2084-5; author reply 2085. 2004